PDF

Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference

LEXINGTON, Mass., Sept. 20, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Annual Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017.

Event: Annual Cantor Fitzgerald Global Healthcare Conference

Date: Wednesday, September 27, 2017

Time: 2:15 PM ET

Location: The InterContinental New York Barclay Hotel in New York City

About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules.¬† Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development as topical eye drops for the treatment of ocular inflammation. ADX-102 has now been tested in over 250 patients in Phase 2 clinical trials in dry eye disease, allergic conjunctivitis, and noninfectious anterior uveitis. A dermatologic form of ADX-102 is in late-stage clinical development for the treatment of ichthyosis due to Sjögren-Larsson Syndrome, an inborn error of aldehyde metabolism. ADX-102 has not been approved for sale in the U.S. or elsewhere.

Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com

Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com

Media Contact:
Cammy Duong
MacDougall Biomedical Communications 
781-591-3443
cduong@macbiocom.com

View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-annual-cantor-fitzgerald-global-healthcare-conference-300522673.html

SOURCE Aldeyra Therapeutics, Inc.

News Provided by Acquire Media